Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00333216
Status:
TERMINATED
Last Update Posted:
2012-11-28
First Post:
2006-05-31
Brief Title:
Anecortave Acetate Risk-Reduction Trial AART
Sponsor:
Alcon Research
Organization:
Alcon Research
Study Overview
Official Title:
Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension 15 mg or 30 mg Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration AMD
Status:
TERMINATED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of efficacy
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension 15 mg or 30 mg is safe and effective in arresting the progression of non-exudative dry age-related macular degeneration in patients who are at risk for progressing to exudative wet age-related macular degeneration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None